J. Stangier

New England Journal of Medicine · 2007–2017

A researcher in the Science corpus: 7 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Papers from J. Stangier's perspective

Ordered by how strongly the researchers J. Stangier trusts endorse each paper. Same corpus, a different order for every researcher.

1. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. (Chest)
2. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. (British Journal of Clinical Pharmacology)
3. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. (New England Journal of Medicine)
4. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (Chest)
5. Managing oral anticoagulant therapy. (Chest)
6. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. (Archives of Internal Medicine)
7. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. (New England Journal of Medicine)
8. Systematic overview of warfarin and its drug and food interactions. (Archives of Internal Medicine)
9. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. (New England Journal of Medicine)
10. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. (New England Journal of Medicine)

Their papers

• Idarucizumab for Dabigatran Reversal — Full Cohort Analysis (2017) — 692 citations
• Idarucizumab for Dabigatran Reversal. (2015) — 1,551 citations
• Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity (2010) — 1,437 citations
• Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate (2010) — 753 citations
• Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate (2008) — 700 citations
• The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans (2008) — 732 citations
• The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. (2007) — 929 citations